Lantheus Holdings Balances Near-Term Pressure, Long-Term Growth

Lantheus Holdings Inc ((LNTH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Lantheus Holdings struck a cautiously optimistic tone in its latest earnings call, highlighting fresh regulatory wins, steady product growth and robust cash generation while acknowledging near‑term margin pressure. Management stressed disciplined spending and preparation for major launches, framing 2026 as a year of investment ahead of an expected growth inflection in 2027.

FDA Approval of PYLARIFY TRUVU

The company’s marquee update was the March 6 approval of PYLARIFY TRUVU, a next‑generation formulation of its flagship PSMA PET agent. TRUVU enables larger batch sizes and better stability at higher radioactive concentrations, and Lantheus noted that more than 70% of current PYLARIFY output already comes from PMF sites ready to exploit these manufacturing advantages.

Total Revenue and Adjusted Growth

First‑quarter revenue came in at $377.3 million, a modest 1.2% rise from a year earlier on a reported basis. Excluding $25.2 million of divested specialty revenues from the prior period, however, underlying growth looked healthier at 8.6%, underscoring resilient demand despite portfolio reshaping and competitive noise.

PYLARIFY Volume Momentum

PYLARIFY remained the workhorse of the oncology franchise with U.S. volumes up about 5.8% year over year. Management pointed out that volumes and net pricing were sequentially stable, suggesting the product is holding its own even as rivals intensify competition and as the company prepares to transition customers to TRUVU.

NEUROCEQ Rapid Growth and Footprint Expansion

NEUROCEQ delivered $35.4 million in revenue for the quarter, up 14.3% versus the fourth quarter of 2025, signaling rapid uptake. The manufacturing footprint has expanded to 22 sites, which should support deeper market penetration and better reliability of supply as the company targets broader neurological imaging demand.

DEFINITY Solid Performance

Legacy ultrasound agent DEFINITY continued to provide dependable growth, posting $84.6 million in revenue, up roughly 6.8% year over year. With market share holding above 80% and usage steady across care settings, DEFINITY remains a cash‑generating anchor for the portfolio as newer franchises scale.

Strength in Strategic Partnerships and Pharma Solutions

Strategic partnerships and other revenue climbed to $16.3 million, a sharp 52.1% increase from the prior year. Management credited the performance of its Pharma Solutions business, bolstered by the Evergreen CDMO acquisition, with MK‑6240 alone accounting for more than half of this segment’s revenue.

Strong Cash Generation and Balance Sheet Flexibility

Operating cash flow reached $125.1 million compared with $107.6 million a year ago, while capital expenditures were held to $3.2 million, yielding free cash flow of $121.9 million. With nearly $499 million in cash and equivalents, $200 million left on its buyback plan and a $750 million undrawn revolver, Lantheus emphasized ample flexibility to fund growth and return capital.

Maintained Full-Year Guidance and 2027 Acceleration Outlook

The company reaffirmed 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted EPS of $5.00 to $5.25, citing a solid start to the year and robust cash generation. Management reiterated that a stronger growth phase is expected to begin in 2027, tied to commercial execution on TRUVU and potential regulatory milestones in its therapeutic and diagnostic pipeline.

Oncology Revenue Decline and Pricing Pressure

Despite volume gains, oncology revenue for PYLARIFY declined 6.5% year over year to $240.9 million, reflecting price pressure and a more crowded PSMA PET market. This divergence between unit growth and reported dollars highlights the challenge of sustaining premium pricing as competitors battle for share and reimbursement dynamics evolve.

Profitability Pressure and Lower Adjusted Earnings

Operating profit fell 10.5% to $129.1 million, and adjusted net income dropped 12.5% to $95.8 million, resulting in adjusted EPS of $1.46, down 4.6%. Management framed the earnings dip as a function of near‑term investment rather than structural deterioration, but investors must weigh the trade‑off between current margin compression and future growth.

Higher Operating Expense Rate

Operating expenses rose to 32.8% of revenue, up 455 basis points year over year, as acquisitions and new launch preparations flowed through the P&L. The company pointed to spending tied to Evergreen and LMI, increased R&D for its pipeline and commercial build‑out for NEUROCEQ and PYLARIFY TRUVU as key drivers of the higher cost base.

Margin Dilution from New Initiatives and Acquisitions

The integration of the Evergreen manufacturing facility and LMI operations contributed to short‑term margin dilution, with elevated G&A, sales and marketing and R&D expenses versus the prior year. Management argued that these investments should enhance long‑term manufacturing scale and commercial capabilities even as they temporarily weigh on profitability.

Regulatory Delays and Conditional Approvals

Not all regulatory news was straightforwardly positive, as the FDA extended the review timeline for Actinium by three months to late June 2026 for manufacturing‑related reasons. Meanwhile, PNT2003 secured tentative approval in early March, but its commercial debut will hinge on the resolution of legal and regulatory constraints, adding some timing uncertainty.

Pricing and Competitive Risks in PSMA PET

Executives acknowledged that PSMA PET pricing and competition remain key swing factors, noting that one rival will lose pass‑through status later this year, which could shift market dynamics. Lantheus signaled a cautious stance in its guidance to account for possible pricing headwinds and evolving competitive behavior in this critical category.

Non‑recurring and Non‑cash Charges

Reported results were also influenced by $28.1 million in net adjustments before tax, including $16.0 million of non‑cash stock‑based compensation and incentives and $16.7 million of acquired intangible amortization. An additional $6.4 million of acquisition, integration and other one‑time costs further depressed GAAP profitability but are not expected to repeat at the same scale.

Forward-Looking Guidance and Outlook

Reiterating full‑year guidance, Lantheus underscored that it is maintaining its outlook partly out of prudence amid competitive shifts and an impending CEO transition. While near‑term earnings will be pressured by investments and pricing dynamics, the company is betting that regulatory catalysts and the PYLARIFY TRUVU rollout will set up a more robust growth trajectory from 2027 onward.

Lantheus’ latest earnings call painted a picture of a company in transition, balancing solid product momentum and cash strength against near‑term profitability headwinds. For investors, the story hinges on whether today’s elevated spending and pricing pressure will be rewarded by the promised 2027 acceleration and successful execution on TRUVU and pipeline milestones.